Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of kidney care company DaVita HealthCare Partners (NYSE: DVA ) surged 10% today after the company signed a standstill agreement with Warren Buffett's Berkshire Hathaway.
So what: Berkshire agreed not to acquire more than 25% of DaVita after approaching management about increasing its stake, indicating that Buffett is possibly setting the stage to negotiate a friendly takeover. Additionally, Berkshire's interest alone suggests that DaVita is undervalued, giving bargain hounds good reason to start sniffing around the shares.
Now what: Don't let today's pop prevent you from looking into the stock.
"Berkshire recently approached us about the option of increasing their holdings," DaVita's Chief Legal Officer Kim Rivera said on a conference call with analysts. "We found them to be a supportive investor with a long-term view."
When you couple DaVita's solid fundamentals and still-reasonable P/E with the possibility of a Berkshire takeover, the stock's risk/reward profile seems rather attractive at this point.
Interested in more info DaVita? Add it to your watchlist.